Carnegie acted as exclusive financial adviser to Exiqon A/S and its owners
Carnegie has advised Exiqon A/S in its issue of a senior secured note in the amount of DKK 40m. The note is fully subscribed by Ture Invest AB, a Stockholm based direct lender and alternative credit investor. Proceeds will mainly be used to further develop the company’s recently launched cloud platform for life science researchers and to accelerate growth by expanding the company’s product offering within RNA analysis.
Exiqon A/S is a market leading niche player within RNA analysis. It develops, manufactures and markets reagents and kits to test the actual contents on a molecular level of biological samples (e.g. urine, blood, etc.). The reagents and kits are used by academia and in the pharmaceutical industry in biological research and development of novel medicines and molecular diagnostic tests.